Analysis of brain cancer platforms and technologies

Analysis of brain cancer platforms and technologies, Cancer Australia

The Australian Brain Cancer Mission (the Mission) was announced on 29 October 2017 and aims to double survival rates and improve the quality of life for patients with brain cancer over ten years to 2027, with the longer-term aim of defeating brain cancer. As administrators of the Mission, Cancer Australia engaged Healthcare Management Advisors (HMA) to undertake the analysis of brain cancer platforms and technologies to identify current and emerging platforms and technologies that are or could be used to support brain cancer across the cancer continuum of research, clinical trials, early detection, diagnosis, treatment, and clinical care. Platform areas included omics, molecular imaging technology, bioinformatics, histology / pathology, model systems, therapeutic technologies, registries and clinical trial collaborations.

A key part of the project included a rapid evidence assessment of peer-reviewed and grey literature from 2016 to 2020 for the eight platform categories including over thirty technologies. The evidence assessment focused on the use of the technology along the cancer continuum in Australia and overseas.

The project commenced in November 2019 and was completed in May 2021.